EMP3 belongs to the peripheral myelin protein 22-kDa (PMP22) gene family as novel therapeutic targets in human cancer, which is the most important indicator of progression-free and metastasis-free survival for patients with urothelial carcinoma of the upper urinary tract (71). This evidence concerns the gene PMP22 and urothelial carcinoma.